Provided by Tiger Trade Technology Pte. Ltd.

CRISPR Therapeutics AG

53.46
-1.1800-2.16%
Post-market: 53.32-0.1437-0.27%19:59 EST
Volume:1.30M
Turnover:69.59M
Market Cap:5.13B
PE:-8.26
High:55.05
Open:54.04
Low:52.92
Close:54.64
52wk High:78.48
52wk Low:30.04
Shares:95.99M
Float Shares:90.53M
Volume Ratio:0.82
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4700
EPS(LYR):-6.4700
ROE:-30.18%
ROA:-15.76%
PB:2.67
PE(LYR):-8.26

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)

TIPRANKS
·
Feb 16

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Benzinga
·
Feb 14

Evercore ISI Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Feb 13

Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

TIPRANKS
·
Feb 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Feb 13

CRISPR Therapeutics Ag : TD Cowen Raises Target Price to $45 From $40

THOMSON REUTERS
·
Feb 13

Cathie Wood's Ark Scoops Up $12.4 Million In Beaten-Down Robinhood — Dumps More Airbnb Shares

Benzinga
·
Feb 13

Switzerland's CRISPR Therapeutics misses Q4 revenue expectations

Reuters
·
Feb 13

CRISPR Therapeutics Q4 EPS $(1.37) Misses $(1.09) Estimate, Sales $864.000K

Benzinga
·
Feb 13

IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed

TIPRANKS
·
Jan 31

Cathie Wood’s ARK Investment buys 127K shares of Crispr Therapeutics today

TIPRANKS
·
Jan 30

Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Movements

Simply Wall St.
·
Jan 29

Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy

TIPRANKS
·
Jan 28

CRISPR Therapeutics AG CFO Prasad Raju Reports Disposal of Common Shares

Reuters
·
Jan 27

CRISPR Therapeutics CEO Samarth Kulkarni Reports Disposal of Common Shares

Reuters
·
Jan 23

BofA Securities Adjusts Price Target on CRISPR Therapeutics AG to $89 From $90, Maintains Buy Rating

MT Newswires Live
·
Jan 22

Is It Time To Reassess CRISPR Therapeutics (CRSP) After Recent Gene Editing Progress?

Simply Wall St.
·
Jan 18

Not Just for Medical Inquiries: AI Healthcare Is Becoming the Next Golden Track

TradingKey
·
Jan 16

CRISPR Therapeutics Advances CTX310 and CTX320 Gene Editing Drugs in New Clinical Trials

Reuters
·
Jan 12

CRISPR Therapeutics AG Outlines 2026 Strategy with CASGEVY® Expansion, Advancement of Cardiovascular and Autoimmune Programs, siRNA Pipeline Growth, and Initiation of New Clinical Trials

Reuters
·
Jan 12